Endurant Capital Management’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-2,240,421
| Closed | -$39.1M | – | 79 |
|
|
2020
Q4 | $39.1M | Buy |
2,240,421
+485,956
| +28% | +$6.82M | 14.11% | 1 |
|
|
2020
Q3 | $20.5M | Buy |
1,754,465
+357,670
| +26% | +$4.75M | 6.07% | 3 |
|
|
2020
Q2 | $18.2M | Sell |
1,396,795
-299,093
| -18% | -$3.59M | 1% | 3 |
|
|
2020
Q1 | $15.7M | Buy |
1,695,888
+477,859
| +39% | +$6.68M | 7.12% | 5 |
|
|
2019
Q4 | $20.2M | Buy |
1,218,029
+228,593
| +23% | +$3.71M | 6.37% | 4 |
|
|
2019
Q3 | $16.5M | Buy |
989,436
+360,200
| +57% | +$4.98M | 5.91% | 5 |
|
|
2019
Q2 | $8.66M | Buy |
629,236
+526,643
| +513% | +$8.05M | 3.41% | 9 |
|
|
2019
Q1 | $1.77M | Sell |
102,593
-358,641
| -78% | -$5.68M | 0.7% | 43 |
|
|
2018
Q4 | $5.89M | Buy |
461,234
+166,005
| +56% | +$2.52M | 3.12% | 12 |
|
|
2018
Q3 | $4.79M | Buy |
295,229
+138,360
| +88% | +$1.98M | 2.13% | 16 |
|
|
2018
Q2 | $2.02M | Sell |
156,869
-8,300
| -5% | -$112K | 0.88% | 30 |
|
|
2018
Q1 | $2.06M | Sell |
165,169
-405,256
| -71% | -$4.93M | 0.77% | 36 |
|
|
2017
Q4 | $7.97M | Sell |
570,425
-161,084
| -22% | -$2.36M | 2.44% | 16 |
|
|
2017
Q3 | $12.3M | Sell |
731,509
-19,025
| -3% | -$310K | 3.72% | 3 |
|
|
2017
Q2 | $12.6M | Buy |
750,534
+179,563
| +31% | +$2.68M | 3.57% | 3 |
|
|
2017
Q1 | $8.84M | Buy |
570,971
+554,915
| +3,456% | +$7.93M | 2.84% | 10 |
|
|
2016
Q4 | $240K | Sell |
16,056
-95,599
| -86% | -$1.34M | 0.1% | 66 |
|
|
2016
Q3 | $1.4M | Buy |
+111,655
| New | +$1.12M | 0.52% | 43 |
|
Endurant Capital Management's OXFD Position: Q1 2021 in Review
Endurant Capital Management sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2021, closing a stake of 2,240,421 shares — an estimated $39.1M sold.
Endurant Capital Management first reported a position in OXFD in Q3 2016 and held it in 18 quarters. The position peaked at $39.1M in Q4 2020. 0 funds tracked by Wall St. Rank hold OXFD as of Q1 2021.
- Endurant Capital Management reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2021 after selling out during the quarter.
- Endurant Capital Management sold 2,240,421 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2021, an estimated $39.1M.
- Endurant Capital Management first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q3 2016 and held it in 18 quarters.
- Endurant Capital Management's Oxford Immunotec Global PLC Ordinary Shares position peaked at $39.1M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2021.
Based on Endurant Capital Management's 13F filing for Q1 2021, filed 17 May 2021.